The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies.

ABSTRACT:

Background

Electrochemiluminescence (ECL) assays have shown promise for enhancing the prediction of type 1 diabetes (T1D) with autoantibodies. We thus studied relatives of T1D patients to determine whether ECL assays can be used to refine risk assessments for T1D among individuals either positive for single GADA or single mIAA autoantibodies.

Subjects and methods

TrialNet Pathway to Prevention (PTP) study participants with either GADA or mIAA single autoantibodies were tested for ECL positivity during their participation in the TrialNet PTP study. Those ECL positive (ECL⁺) were compared with those ECL negative (ECL^-) for conversion to multiple autoantibodies, 6-month glycemic progression (PS6M), and the progression to T1D.

Results

The progression

SUBMITTER: Sosenko JM 

PROVIDER: S-EPMC5359659 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature